Discovery and Development of a Small Molecule Library with Lumazine Synthase Inhibitory Activity by Talukdar, Arindam et al.
Discovery and Development of a Small Molecule Library with
Lumazine Synthase Inhibitory Activity
Arindam Talukdar†, Megan Breen†, Adelbert Bacher‡, Boris Illarionov§, Markus Fischer§,
Gunda Georg¶, Qi-Zhuang Ye¶, and Mark Cushman*,†
†Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and
Pharmaceutical Sciences, and The Purdue Cancer Center, Purdue University, West Lafayette,
Indiana 47907
‡Ikosatec GmbH, Königsbergerstr. 74, 85748 Garching, Germany
§Institute of Food Chemistry, University of Hamburg, D-20146 Hamburg, Germany
¶Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047
Abstract
(E)-5-Nitro-6-(2-hydroxystyryl)pyrimidine-2,4(1H,3H)-dione (9) was identified as a novel inhibitor
of Schizosaccharomyces pombe lumazine synthase by high-throughput screening of a 100,000
compound library. The Ki of 9 vs. Mycobacterium tuberculosis lumazine synthase was 95 μM.
Compound 9 is a structural analog of the lumazine synthase substrate, 5-amino-6-(D-
ribitylamino)-2,4-(1H,3H)pyrimidinedione (1). This indicates that the ribitylamino side chain of the
substrate is not essential for binding to the enzyme. Optimization of the enzyme inhibitory activity
through systematic structure modification of the lead compound 9 led to (E)-5-nitro-6-(4-nitrostyryl)
pyrimidine-2,4(1H,3H)-dione (26), which has a Ki of 3.7 μM vs. M. tuberculosis lumazine synthase.
Introduction
Riboflavin (4, vitamin B2) plays a crucial role in many biological processes, including
photosynthesis and mitochondrial electron transport. While animals obtain riboflavin from
dietary sources, numerous microorganisms, including Gram-negative pathogenic bacteria and
yeasts, lack an efficient riboflavin uptake system and are therefore absolutely dependent on
endogenous riboflavin biosynthesis.1-4 Riboflavin biosynthesis therefore offers attractive
targets for the design and synthesis of new antibiotics, which are urgently needed because
pathogens are becoming drug-resistant at an alarming rate.
Lumazine synthase and riboflavin synthase catalyze the last two steps in the biosynthesis of
riboflavin (4) (Scheme 1). Lumazine synthase catalyzes the condensation of 3,4-dihydroxy-2-
butanone 4-phosphate (2) with 5-amino-6-ribitylamino-2,4(1H,3H)pyrimidinedione (1),
yielding 6,7-dimethyl-8-D-ribityllumazine (3).5,6 The final step in the biosynthesis involves a
mechanistically unusual dismutation of two molecules of 3, resulting in the formation of one
molecule of riboflavin (4) and one molecule of the pyrimidinedione derivative 1, which can
then be recycled by lumazine synthase.7-15
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Although the details of the reaction catalyzed by lumazine synthase have not been completely
elucidated, a reasonable pathway can be outlined at the present time as depicted in Scheme 2.
Condensation of the primary amino group of the substituted pyrimidinedione 1 with the ketone
2 to give Schiff base 5, elimination of phosphate to yield the enol 6, tautomerization of the enol
6 and isomerization of the imine to produce the ketone 7, ring closure, and dehydration of the
covalent hydrate 8 provide the product 3.16 It can be assumed that the inorganic phosphate
formed after elimination from 5 would remain enzyme bound, at least for some time, but that
it would eventually have to be removed to make room for another molecule of the substrate
2. The present uncertainties revolve around the timing of phosphate elimination and the
conformational reorganization of the side chain leading to intermediate 7.
A high-throughput screening (HTS) technique was developed based on competitive binding
of lumazine synthase inhibitors and riboflavin to the active site of Schizosaccharomyces
pombe lumazine synthase.17,18 The capacity of the S. pombe lumazine synthase to bind
riboflavin is unique. Free riboflavin is fluorescent with high quantum yield while enzyme-
bound riboflavin is not.19 Thus, displacement of riboflavin from the binding pocket results in
a significant fluorescence increase of the system. The change in fluorescence caused by
competitive binding between riboflavin and other ligands for S. pombe lumazine synthase was
used to identify lumazine synthase inhibitors.17 All of the known inhibitors tested were
positively identified, which confirmed the authenticity of this assay. HTS of a commercial
100,000 compound library yielded some interesting results, including the identification of a
lead compound 9.
The thermodynamic HTS assay described above effectively bypasses the problems associated
with the instabilities of the lumazine synthase substrates 1 and 2, and it also simplifies the assay
by removing the time element. However, practically speaking, it had two limitations: 1) assay
mixtures contained traces of free riboflavin that produced a fluorescent background; and 2)
lumazine synthase inhibitors that bind outside the active site would probably be unable to
release free riboflavin. In spite of these problems, the thermodynamic assay remained the
method of choice for screening thousands of compounds, and the activities of the hit
compounds were confirmed in secondary assays involving classical enzyme kinetics.
Our specific interest in compound 9 is the result of its structural similarity to the substrate 1.
The identification of 9 as a lumazine synthase inhibitor represents an extension of ongoing
work on the synthesis of metabolically stable intermediates in the lumazine synthase-catalyzed
reaction.20-23 The HTS hit compound 9 demonstrates that the ribitylamino chain present in the
substrate, which was thought to be necessary for binding to the enzyme, can be replaced by a
simple hydroxystyryl moiety with retention of lumazine synthase inhibitory activity. The
difference in physical properties between compounds 1 and 9 has significant implication for
antibiotic drug development. Substrate analogs with ribityl side chains are not suitable as drug
candidates because their hydrophilic nature can be expected to prevent them from penetrating
bacterial cell walls. Gram negative bacterial cell walls contains an outer membrane composed
of phospholipids and lipopolysaccharides that face toward external environment. Replacing
the hydrophilic ribityl side chain of compound 1 with the styryl moiety renders compound 9
more lipophilic, which should facilitate the entry of the compound into bacteria. Compound
9 displayed Ki values of 210 μM vs. S. pombe lumazine synthase and 95 μM vs. Mycobacterium
tuberculosis lumazine synthase. Thus, there is ample room for designing more potent lumazine
synthase inhibitors based on the structure of the lead compound 9. Moreover, the lead
compound 9 is a substrate analog of the lumazine synthase–catalyzed reaction, but it is also a
product analog of the riboflavin synthase-catalyzed reaction. Structural analogs of 9 might
therefore be expected to inhibit riboflavin synthase as well as lumazine synthase. Enzyme
assays were therefore performed using the riboflavin synthases of M. tuberculosis and E.
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coli. In order to help define the spectrum of activity, lumazine synthase inhibition assays were
also performed on M. tuberculosis lumazine synthase as well as S. pombe lumazine synthase.
Results and Discussion
The lumazine synthase inhibitory activity of the HTS hit compound 9 might be related to the
presence of the phenolic hydroxy on the aromatic ring, which could possibly mimic one of the
ribityl hydroxyl groups of the substrate 1. In addition, it is known that the substrate analog
10, which also contains a nitro group, has high affinity for the active site of lumazine synthase
and has been crystallized in complex with Bacillus subtilis lumazine synthase.24,25 Molecular
modeling was performed in order to investigate the binding mode of the hit compound 9 to the
enzyme. The lead compound 9 was docked into the active site of the structure of
Mycobacterium tuberculosis lumazine synthase26,27 using GOLD software (BST, version 3.0,
2005), and energy minimization was then performed with Sybyl 7.1. The resulting structure is
displayed in Figure 1. According to this hypothetical model, the binding of the hit compound
9 in the active site of M. tuberculosis lumazine synthase is similar to that of substrate and
product analogs.26-28 The structure involves hydrogen bonding of the phenolic hydroxyl group
of 9 with Ala59, Ile60, and Glu61. In addition, stacking interactions involving Trp27 stabilize
the binding. The molecular modeling results indicate that the binding of hit compound 9 in the
active site of M. tuberculosis lumazine synthase is certainly plausible, and it most likely
resembles the known crystal structure of the complex formed between the related substrate
analog 10 and the enzyme.
We have attempted to employ versatile methods that would allow the efficient synthesis of a
wide variety of target molecules. Accordingly, an array of aromatic aldehydes were condensed
with 6-methyl-5-nitrouracil to afford a focused library of alkenes with pure trans geometry.
29-31 No attempt was made to synthesize cis alkenes because the preliminary ligand docking
studies indicated unfavorable interactions in the active site. As outlined in Scheme 3, nitration
of 6-methyluracil (11) in the presence of H2SO4 and fuming nitric acid furnished 6-methyl-5-
nitrouracil (12).32 Condensation of compound 12 with aromatic aldehydes in the presence of
piperidine provided the piperidine salts of 5-nitro-6-styryluracil derivatives 13. The piperidine
salts were neutralized by the addition of excess hydrochloric acid to give pure 5-nitro-6-
styryluracil derivatives. The presence of the nitro group at the 5-position activates the methyl
group for the reaction with piperidine acting as the basic catalyst.
The protocol did indeed seem to be versatile until the condensation was attempted with 2-
nitrobenzaldehyde, 4-nitrobenzaldehyde, and 2,3-dihydroxybenzaldehyde. In those cases, the
reaction did not produce the desired products, which is consistent with earlier literature reports.
33 The protocol was therefore modified (Scheme 4) to provide the required 2-nitro derivative
14 and the other desired condensation products. Instead of using piperidine as the solvent,
which initially resulted in the piperidine salt of the condensation product, the reaction was
performed in 1-butanol, a high-boiling alcohol, in the presence of one equivalent of piperidine.
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Two classes of compounds were synthesized as shown in structures 9, 15-18 (Class 1) and
19-24 (Class 2). The enzyme inhibitory activities of these compounds were determined using
lumazine synthases from M. tuberculosis and S. pombe, and riboflavin synthases from
Escherichia coli and M. tuberculosis. The results are listed in Table 1.
The hit compound 9 exhibits a Ki of 210 μM vs. S. pombe lumazine synthase and a Ki of 95
μM vs. M. tuberculosis lumazine synthase. To determine the effect of the position of the
hydroxy group in the phenyl ring on the enzyme inhibitory activity, Class I compounds were
synthesized. Compound 15, with a 3-hydroxy group, and compound 16, with a 4-hydroxy
group, showed marked increases in inhibitory activity, with the 3-hydroxy compound 15
exhibiting a Ki of 7.1 μM and 4-hydroxy compounds 16 exhibiting a Ki 12 μM vs. M.
tuberculosis lumazine synthase. Both compounds 15 and 16 displayed remarkable selectivity
for inhibition of M. tuberculosis lumazine synthase, being completely ineffective against S.
pombe lumazine synthase and E. coli riboflavin synthase. Thus, changing the position of the
phenol improved both the inhibitory activity vs. M. tuberculosis lumazine synthase as well as
the selectivity.
The presence of two hydroxyl groups on compounds 17 and 18 changed the inhibitory activity
profile drastically. Both of these compounds were found to be potent against M. tuberculosis
lumazine synthase, M. tuberculosis riboflavin synthase, S. pombe lumazine synthase, and E.
coli riboflavin synthase, with compound 17 being more potent than compound 18. Compound
17 exhibited a broader spectrum enzyme-inhibitory profile than the hit compound 9, with a
Ki of 12 μM vs. M. tuberculosis lumazine synthase, a Ki of 19 μM vs. M. tuberculosis riboflavin
synthase, a Ki of 4.9 μM vs. S. pombe lumazine synthase, and Ki of 10 μM vs. E. coli riboflavin
synthase.
The hypothetical structural model of hit compound 9 in M. tuberculosis lumazine synthase
(Figure 1) indicates that the hydroxy group may hydrogen bond with the Ala59, Ile60 and
Glu61 amino acid residues. Class II compounds were synthesized in order to determine the
importance of hydrogen bond donor and acceptor properties. Class II compounds with
OCH3 groups displayed slightly better potencies than their counterparts with OH groups.
Compound 21 exhibited a Ki of 9.6 μM vs. M. tuberculosis lumazine synthase, whereas
compound 17 showed a Ki of 12 μM vs. M. tuberculosis lumazine synthase. Similarly,
compound 19 exhibited Ki of 28 μM vs. M. tuberculosis lumazine synthase, whereas hit
compound 9 displayed a Ki of 95 μM vs. M. tuberculosis lumazine synthase.
In Class III compounds, the hydroxyl groups have been replaced with different functional
groups that can also participate in hydrogen bonding. Compounds with a NO2 group showed
a marked increase in inhibitory activity as compared to the lead compound 9. Compound 14
exhibited a Ki of 16 μM vs. M. tuberculosis lumazine synthase, whereas the hit compound 9
had a Ki of 95 μM vs. M. tuberculosis lumazine synthase. The 4-NO2 derivative 26 displayed
the best inhibitory activity, with a Ki of 3.7 μM vs. M. tuberculosis lumazine synthase. Among
the compounds with different halogens, the 2-fluoro derivative 28 had the best activity with
Ki of 7.8 μM vs. M. tuberculosis lumazine synthase. Thus, improved inhibitors of M.
tuberculosis lumazine synthase were obtained by changing the OH group in the hit compound
9 to a NO2 group or to F.
Classes I-III yielded two compounds 26 and 15 with optimized inhibitory activity. Based on
these results, class IV compounds were designed with two different hydrogen bonding groups
in the benzene ring. This may result in the phenyl substituent more closely mimicking the
ribityl chain of the substrate, with more opportunities for hydrogen bonding to the protein.
These inhibitors were prepared following the standard protocol, with 1-butanol as the solvent
and one equivalent of piperidine as the base.
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The enzyme inhibitory activities of the Class IV compounds were disappointing. In fact, they
had less inhibitory activity than their counterparts with single functional groups. Compound
35 showed the best inhibitory profile, with a Ki of 12 μM against M. tuberculosis lumazine
synthase. These discouraging results prompted a reevaluation of the hypothesis that the
functional groups on the aromatic ring hydrogen bond with the amino acid residues in the active
site of M. tuberculosis lumazine synthase. This led to the synthesis of compounds 39 and 43
in the series of Class V compounds, which contain unsubstituted aromatic rings. Compound
39 was expected to be a very weak inhibitor, but to the contrary, it was found to have good
inhibitory activity, with a Ki of 15 μM vs. M. tuberculosis lumazine synthase, which is much
better than the hit compound 9 (Ki 95 μM vs. M. tuberculosis lumazine synthase). Compound
43, with a naphthyl substituent, exhibited even better inhibitory activity, with a Ki of 11 μM
vs. M. tuberculosis lumazine synthase.
In Class VI compounds, the alkene linker is replaced by more flexible ethylene and
aminomethylene connectors. The increase in conformational freedom should confer greater
similarity with the substrate 1.
Compounds 45 and 46 were synthesized (Scheme 5) by treating 6-chloro-5-nitrouracil (52)
with benzylamines 53 and 54 in presence of triethylamine. The free bases were liberated from
their triethylamine salts by dissolving them in aq KOH and neutralizing with dilute HCl
solution.
Compounds 47 and 48 were prepared by selective reduction of the trans alkene linkers present
in 9 and 16. The presence of the reducible NO2 group and conjugated double bond in
compounds 9 and 16 made these alkenes difficult to selectively reduce. The usual protocol
involving Pd/C reduced both the NO2 group and the double bond. After unsuccessful attempts
to selectively reduce either the double bond or the nitro group with Fe or Zn in acetic acid, Zn
and hydrazinium monoformate, and Na2S2O4, it was discovered that hydrogenation over
Lindlar catalyst resulted in selective reduction of the alkene linker without reduction of the
NO2 group.
Compound 49 was accidentally formed during the condensation reaction of compound 12 with
2-formylbenzoic acid. Evidently, the alcohol intermediate formed from 12 and 2-
formylbenzoic acid lactonizes to 49 instead of dehydrating to the alkene. The structure of the
lactone 49 suggests that 5-nitro-6-styryluracil derivatives might be susceptible to nucleophilic
attack on the exocyclic double bond, but no instance of this was observed in the present series
of compounds, which in general were quite stable.
The NO2 group and the trans double bond in 9 and 39 were simultaneously reduced by
hydrogenation using Pd/C to obtain compounds 50 and 51. This completes the synthesis of
Class VI compounds.
All compounds in Class VI are either completely inactive or have very weak inhibitory activity.
Molecular modeling was performed in order to investigate the possible bonding mode of
compound 46 to the enzyme. The compound 46 was docked into the M. tuberculosis lumazine
synthase structure using Gold software (BST, version 3.0, 2005). Energy minimization was
then performed using Sybyl 7.1. The resulting structure is displayed in Figure 2. According to
the theoretical model, the binding of the 2-hydroxyphenyl moiety of 46 in the active site of M.
tuberculosis lumazine synthase is similar to the high-throughput screening compound 9.
However, the model indicates that the uracil ring of 46 does not stack with Trp 27, which may
explain the inactivity of 45-48.
In conclusion, high-throughput screening of a 100,000 compound commercial library led to
the identification of the hit compound 9, which displayed a Ki of 95 μM vs. M. tuberculosis
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lumazine synthase. The design and synthesis of a focused array of structural analogs provided
the optimized congener 26, which had a Ki of 3.7 μM vs. M. tuberculosis lumazine synthase.
Both of these compounds are structural analogs of the lumazine synthase substrate 1 and the
known lumazine synthase ligand 10. The results of this study show that the ribitylamino side
chain of the ligand 10 can be replaced by substituted styryl moieties with retention of affinity
for the enzyme. The circumvention of the ribitylamino side chain may contribute positively to
antibiotic drug development because its polarity is expected to limit uptake by bacterial cells.
As expected from the fact that the pyrimidinedione 1 is a substrate of the lumazine synthase-
catalyzed reaction and an product of the riboflavin synthase-catalyzed reaction, many of the
styryl derivatives in the present series, including 9, 17, 18, 29, 32, 33, 35, 40, 43, 44, 48, and
50, inhibited both enzymes. This is a potential advantage because drug resistance is less likely
to emerge from target mutation with antibiotics that act on two targets, since resistance
mutations would have to emerge in both targets at the same time for the organism to become
drug resistant. Although it was previously demonstrated that the intermediate analog 55, in
which the ribityl group is replaced by a chlorine atom, has affinity for lumazine synthase,
compound 55 also has a phosphate moiety that contributes positively to binding.27 It therefore
contrasts to the present series of inhibitors, which do not contain a phosphate moiety.
Experimental Section
General Procedure Method A
5-Nitro-6-methyluracil (12) (1.0 g, 5.85 mmol), benzaldehyde derivatives (29.2 mmol) and
piperidine (10 mL) were heated at first on a boiling water-bath until the mixture had thickened
and then for 30 min in an oil-bath at 150 °C. The mixture was diluted with methanol (15 mL),
and the crystalline solid was filtered, washed with a methanol (5 mL) and ether (10 mL), and
dried to give the piperidine salt. The salt was dissolved in dilute KOH solution. On the addition
of excess of hydrochloric acid to the warm solution, a yellow powder precipitated. This was
filtered and washed first with water (2 × 10 mL) and methanol (2 × 10 mL), and then with ether
(2 × 10 mL) to give the desired condensation product.
(E)-6-(3-Hydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (15)—A yellow
amorphous solid 15 (1.20 g. 75%): mp 238-240 °C (dec). 1H NMR (300 MHz, CDCl3) δ 7.53
(d, J = 16.4 Hz, 1 H), 7.16 (t, J = 7.8 Hz, 1 H), 6.97 (d, J = 7.6 Hz, 1 H), 6.92 (s, 1 H), 6.86 (d,
J = 16.4 Hz, 1 H), 6.77 (d, J = 8.1 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 158.0, 156.9,
149.4, 147.8, 142.3, 135.8, 130.5, 126.7, 119.7, 118.3, 114.4, 113.8; EIMS m/z 275 (M+). Anal.
Calcd for C12H9N3O5: C, 52.37; H, 3.30; N, 15.27. Found: C, 52.58; H, 3.14; N, 15.54.
(E)-6-(4-Hydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (16)—An orange
amorphous solid 16 (1.25 g, 78%): mp 230-232 °C (dec). 1H NMR (300 MHz, CDCl3) δ 7.64
(d, J = 16.3 Hz, 1 H), 7.52 (d, J = 8.64 Hz, 2 H), 6.87 (J = 8.64 Hz, 2 H), 6.85 (d, J = 16.3 Hz,
1 H); 13C NMR (75 MHz, DMSO-d6) δ 160.6, 156.9, 149.5, 148.0, 142.7, 130.8, 126.1, 125.7,
116.3, 109.9; negative ion EIMS m/z 549 [(2M − H+)−, 100], 275 (M, 11), 274 [(M − H+)−,
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98], 144 (4). Anal. Calcd for C12H9N3O5: C, 52.37; H, 3.30; N, 15.27. Found: C, 52.45; H,
3.24; N, 15.58.
(E)-6-(3-Hydroxy-4-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (20)—A
red amorphous solid 20 (625 mg, 67%): mp 300-304 °C. 1H NMR (300 MHz, DMSO-d6) δ
9.34 (s, 1 H), 7.68 (d, J = 16.2 Hz, 1 H), 7.06 (s, 1 H), 7.04 (d, J = 7.8 Hz, 1 H), 6.98 (d, J =
7.8 Hz, 1 H), 6.69 (d, J = 16.2 Hz, 1 H), 3.81 (s, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 156.8,
150.7, 149.4, 147.8, 147.0, 142.5, 127.1, 126.0, 121.8, 113.9, 112.2, 110.7, 55.7; negative ion
EIMS m/z 609 [(2M − H+)−, 46], 304 [(M − H+)−, 100]. Anal. Calcd for C13H11N3O6: C, 51.15;
H, 3.63; N, 13.77. Found: C, 50.80; H, 3.80, N, 13.43.
(E)-6-(2,3-Dimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (21)—An orange,
amorphous solid 21 (655 mg, 70%): mp 280-283 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.25
(d, J = 16.5 Hz, 1 H), 6.57 (m, 1 H), 6.48 (m, 1 H), 6.36 (d, J = 16.2 Hz, 1 H), 3.18 (s, 3 H),
3.14 (s, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 157.1, 153.3, 149.8, 148.5, 148.1, 137.1, 128.4,
127.0, 124.9, 119.6, 115.5, 115.3, 61.2, 56.0; negative ion EIMS m/z 637 [(2M − H+)−, 100],
318 [(M − H+)−, 46]. Anal. Calcd for C14H13N3O6.·0.5H2O: C, 51.22; H, 4.30; N, 12.80.
Found: C, 51.03; H, 3.91, N, 12.53.
(E)-6-(3,4-Dimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (22)—A red
amorphous solid 22 (625 mg, 67%): mp 328-230 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.67
(d, J = 16.2 Hz, 1 H), 7.23 (d, J = 1.6 Hz, 1 H), 7.16 (dd, J = 1.6 Hz, 8.4 Hz, 1 H), 7.00 (d, J
= 8.4 Hz, 1 H), 6.85 (d, J = 16.2 Hz, 1 H), 3.80 (s, 3 H), 3.77 (s, 3 H); 13C NMR (75 MHz,
DMSO-d6) δ 156.7, 151.5, 149.4, 149.1, 147.9, 142.3, 127.1, 126.0, 123.5, 111.7, 111.3, 110.0,
55.7; Negative ion EIMS m/z 637 [(2M − H+)−, 14], 318 [(M − H+)−, 100]. Anal. Calcd for
C14H13N3O6: C, 52.67; H, 4.10; N, 13.16. Found: C, 52.69; H, 3.87, N, 13.01.
(E)-6-(2,3,4-Trimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (23)—A red
amorphous solid 23 (610 mg, 60%): mp 308-310 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.81
(d, J = 16.8 Hz, 1 H), 7.39 (d, J = 9.5 Hz, 1 H), 6.95 (d, J = 16.8 Hz, 1 H), 6.88 (d, J = 9.5 Hz,
1 H), 3.88 (s, 3 H), 3.86 (s, 3 H), 3.79 (s, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 157.6, 155.6,
152.8, 149.4, 149.1, 141.9, 137.1, 126.1, 124.0, 120.7, 112.7, 108.3, 61.4, 60.6, 56.1; negative
ion EIMS m/z 697 [(2M − H+)−, 100], 348 [(M − H+)−, 57]. Anal. Calcd for C15H15N3O7: C,
51.58; H, 4.33; N, 12.03. Found: C, 51.49; H, 4.35, N, 11.75.
(E)-6-(3,4,5-Trimethoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (24)—A red
amorphous solid 24 (610 mg, 60%): mp 293-296°C (dec). 1H NMR (300 MHz, DMSO-d6) δ
7.56 (d, J = 16.2 Hz, 1 H), 6.94 (d, J = 16.2 Hz, 1 H), 6.92 (s, 2 H), 3.76 (s, 3 H), 3.67 (s, 6 H);
negative ion EIMS m/z 697 [(2M − H+)−, 43], 348 [(M − H+)−, 100]. Anal. Calcd for
C15H15N3O7·1.25H2O: C, 48.46; H, 4.74; N, 11.30. Found: C, 48.27; H, 4.71, N, 11.09.
(E)-6-(2-Fluorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (28)—An orange,
amorphous solid 28 (510 mg. 63%): mp 280-283 °C (dec). 1H NMR (300 MHz, MeOH-d4) δ
7.82 (d, J = 16.5 Hz, 1 H), 7.78 (m, 1 H), 7.50 (m, 1 H), 7.33 (d, J = 8.9 Hz, 1 H), 7.27 (d, J =
7.1 Hz, 1 H), 7.07 (d, J = 16.5 Hz, 1 H); 13C NMR (75 MHz, MeOH-d4) δ 162.5, 156.6, 149.3,
147.5, 133.8, 132.8, 129.1, 126.6, 125.2, 116.6, 116.5. Anal. Calcd for C12H8FN3O4: C, 51.99;
H, 2.91; N, 15.16. Found: C, 51.79; H, 3.05, N, 15.25.
(E)-6-(4-Fluorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (29)—A red amorphous
solid 29 (488 mg. 60%): mp 286-288 °C. 1H NMR (300 MHz, MeOH-d4) δ 7.73 (d, J = 16.0
Hz, 1 H), 7.45 (d, J = 8.3 Hz, 2 H), 6.94 (d, J = 8.4 Hz, 2 H), 6.66 (d, J = 16.0 Hz, 1 H); 13C
NMR (75 MHz, MeOH-d4) δ 156.7, 152.7, 149.3, 147.9, 142.7, 130.3, 125.3, 122.8, 114.2,
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107.6; negative ion EIMS m/z (rel intensity) 276 [(2M − H+)−, 100), 113 (2). Anal. Calcd for
C12H8FN3O4·0.1H2O: C, 51.66; H, 2.96; N, 15.06. Found: C, 51.95; H, 3.22, N, 14.69.
5-Nitro-6-styryluracil (39)—A yellow amorphous solid 39 (5.1 g. 84%): mp 308-310 °C
(lit.33 312-314 °C). 1H NMR (300 MHz, MeOH-d4) δ 7.78 (d, J = 16.2 Hz, 1 H), 7.63 (m, 2
H)(, 7.44 (m, 3 H), 6.98 (d, J = 16.2 Hz, 1 H); 13C NMR (75 MHz, MeOH-d4) δ 157.0, 149.6,
147.2, 134.6, 131.1, 129.5, 128.6, 126.8, 114.2; negative ion EIMS m/z 259 (M, 12), 258 [(M
− H+)−, 98.5], 113 (2). Anal. Calcd for C12H9N3O4: C, 55.60; H, 3.50; N, 16.21. Found: C,
55.89; H, 3.41; N, 15.95.
(E)-5-Nitro-6-(2-(pyridine-2-yl)vinyl)pyrimidine-2,4(1H,3H)-dione (41)—An orange
amorphous solid 41 (1.29 g. 85%): mp 290-292 °C (dec). 1H NMR (300 MHz, CDCl3) δ 8.63
(d, J = 4.8 Hz, 1 H), 7.92 (t, J = 8.6 Hz, 1 H), 7.73 (d, J = 15.9 Hz, 1 H), 7.60 (d, J = 7.8 Hz,
1 H), 7.44 (d, J = 15.9 Hz, 1 H), 7.43 (m, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 157.2, 150.6,
149.2, 148.3, 147.2, 141.3, 137.7, 128.0, 126.5, 126.4, 120.4; negative ion EIMS m/z 541
[(2MNa − 2H+)−, 100], 259 [(M − H+)−, 41]. Anal. Calcd for C11H8N4O4: C, 50.77; H, 3.10;
N, 21.53. Found: C, 50.52; H, 3.16; N, 21.20.
(E)-5-Nitro-6-(3-(pyridine-3-yl)vinyl)pyrimidine-2,4(1H,3H)-dione (42)—A yellow
amorphous solid 42 (1.22 g. 80%): mp 300-303 °C. 1H NMR (300 MHz, CDCl3) δ 8.76 (s, 1
H), 8.59 (d, J = 3.7 Hz, 1 H), 8.13 (d, J = 8.07 Hz, 1 H), 7.70 (d, J = 16.2 Hz, 1 H), 7.46 (dd,
J = 4.8 Hz, 7.8 Hz, 1 H), 7.19 (d, J = 16.2 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 156.8,
151.03, 150.0, 149.8, 148.6, 137.8, 134.4, 130.3, 126.5, 124.2, 117.2; negative ion EIMS m/
z 556.8 [(2M − 2H+)−, 100), 259 [(M − H+)−, 94], 156 (1). Anal. Calcd for C11H8N4O4: C,
50.77; H, 3.10; N, 21.53. Found: C, 50.47; H, 2.88; N, 21.71
General Procedure Method B
5-Nitro-6-methyluracil (12) (0.5 g, 2.92 mmol), benzaldehyde derivatives (5.84 mmol) and
piperidine (0.3 mL, 3.21 mmol) in 1-butanol (10 mL) were heated at first to 100 °C until the
mixture had thickened, and then at reflux for 6 h. The mixture was cooled to room temperature,
filtered, and washed with a methanol (5 mL) and ether (10 mL). The salt was dissolved in dilute
KOH solution, acidified with an excess of hydrochloric acid, and the solid was filtered and
washed with water (2 × 10 mL) and methanol (2 × 10 mL), and then with ether (2 × 10 mL)
and dried to give the desired condensation product.
(E)-6-(2-Nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (14)—A brown amorphous
solid 14 (0.62 mg, 69%): mp 298-300 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.03 (d, J = 8.1
Hz, 1 H), 7.97 (d, J = 9.0 Hz, 1 H), 7.95 (d, J = 16.2 Hz, 1 H), 7.79 (t, J = 7.5 Hz, 1 H), 7.68
(d, J = 7.5 Hz, 1 H), 7.05 (d, J = 16.2 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 156.9, 149.3,
148.8, 147.0, 135.6, 134.0, 131.3, 129.2, 128.9, 127.0, 125.0, 119.3; negative ion EIMS m/z
(rel intensity) 607 [(2M − H+)−, 100], 303 [(M − H+)−, 80], 240 (10). Anal. Calcd for
C12H8N4O6: C, 47.38; H, 2.65; N, 18.42. Found: C, 47.45; H, 2.45; N, 18.10.
(E)-6-(2,3-Dihydroxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (17)—A brown
amorphous solid 17 (0.49 g, 58%): mp 287-290 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ
7.88 (d, J = 15.7 Hz, 1 H), 7.07 (d, J = 15.7 Hz, 1 H), 6.85 (m, 2 H), 6.67 (t, J = 7.8 Hz, 1
H); 13C NMR (75 MHz, DMSO-d6) δ 156.1, 150.0, 149.5, 148.8, 147.4, 138.3, 125.4, 120.7,
119.3, 116.9, 114.2, 112.8; negative ion EIMS m/z 581 [(2M − H+)−, 62], 290 [(M − H+)−,
100]. Anal. Calcd for C12H9N3O6: C, 49.49; H, 3.12; N, 14.43. Found: C, 49.61; H, 3.22; N,
14.48.
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amorphous solid 18 (0.19 g, 23%): mp 279-282 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ
9.78 (brs, 1 H), 7.80 (d, J = 15.8 Hz, 1 H), 7.04 (d, J = 15.8 Hz, 1 H), 6.81 (d, J = 1.97 Hz, 1
H), 6.70 (m, 2 H); 13C NMR (75 MHz, DMSO-d6) δ 156.3, 149.9, 149.5, 148.9, 147.4, 138.5,
125.5, 120.7, 119.3, 116.7, 114.2, 112.7; negative ion EIMS m/z (rel intensity) 581 [(2M −
H+)−, 100], 290 [(M − H+)−, 54], 244 (1). Anal. Calcd for C12H9N3O6: C, 49.49; H, 3.12; N,
14.43. Found: C, 49.78; H, 3.14; N, 14.29.
(E)-6-(2-Methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (19)—A yellow
amorphous solid 19 (0.56 g, 66%): mp 289-300 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.90
(d, J = 16.4 Hz, 1 H), 7.57 (d, J = 7.6 Hz, 1 H), 7.42 (t, J = 7.6 Hz, 1 H), 7.09 (d, J = 7.6 Hz,
1 H), 7.08 (d, J = 16.4 Hz, 1 H), 7.00 (d, J = 7.6 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ
158.3, 156.8, 149.5, 148.1, 137.6, 132.4, 129.5, 126.4, 122.8, 121.0, 114.6, 112.0, 55.8;
negative ion EIMS m/z 577 [(2M − H+)−, 100], 288 [(M − H+)−, 58]. Anal. Calcd for
C13H11N3O5: C, 53.98; H, 3.83; N, 14.53. Found: C, 53.92; H, 3.92; N, 14.17.
(E)-5-Nitro-6-(3-nitrostyryl)pyrimidine-2,4(1H,3H)-dione (25)—A yellow amorphous
solid 25 (0.56 g, 63%): mp 278-280 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.44 (s, 1 H), 8.23
(dd, J = 1.44 Hz, 8.06 Hz, 1 H), 8.06 (d, J = 7.7 Hz, 1 H), 7.76 (d, J = 16.3 Hz, 1 H), 7.70 (d,
J = 8.06 Hz, 1 H), 7.25 (d, J = 16.3 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 156.6, 149.5,
148.3, 147.8, 138.9, 136.0, 134.3, 130.6, 126.8, 124.7, 122.5, 117.7; negative ion EIMS m/z
607 [(2M − H+)−, 100], 303 [(M − H+)−, 37]. Anal. Calcd for C12H8N4O6: C, 47.38; H, 2.65;
N, 18.42. Found: C, 47.02; H, 2.73; N, 18.13.
(E)-5-Nitro-6-(4-nitrostyryl)pyrimidine-2,4(1H,3H)-dione (26)—A brown amorphous
solid 26 (0.62 mg, 69%): mp 304-308 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ 8.23 (d, J
= 8.8 Hz, 2 H), 7.89 (d, J = 8.8 Hz, 2 H), 7.68 (d, J = 15.8 Hz, 1 H), 7.38 (d, J = 15.8 Hz, 1
H); 13C NMR (75 MHz, DMSO-d6) δ 156.7, 149.3, 148.1, 147.6, 140.6, 138.9, 129.3, 127.0,
124.3, 118.7. Anal. Calcd for C12H8N4O6: C, 47.38; H, 2.65; N, 18.42. Found: C, 47.52; H,
2.70, N, 18.19.
(E)-4-(2-(5-Nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)benzoic Acid
(27)—A pale-yellow amorphous solid 27 (0.28 mg, 64%): mp 342-345 °C. 1H NMR (300
MHz, DMSO-d6) δ 11.83 (brs, 1 H), 7.98 (brs, 1 H), 7.95 (brs, 1 H), 7.72 (d, J = 16.3 Hz, 1
H), 7.71 (m, 2 H), 7.07 (d, J = 16.3 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 167.2, 156.8,
149.9, 147.7, 140.8, 138.2, 130.4, 128.2, 127.0, 116.8; negative ion EIMS m/z 605 [(2M −
H+)−, 100], 302 [(M − H+)−, 70]. Anal. Calcd for C13H9N3O6 0.5H2O: C, 50.01; H, 3.23; N,
13.46. Found: C, 50.29; H, 2.89; N, 13.22.
(E)-5-Nitro-6-(4-bromostyryl)pyrimidine-2,4(1H,3H)-dione (30)—A yellow
amorphous solid 30 (0.62 g, 63%): mp 296-298 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ
7.68 (d, J = 16.3 Hz, 1 H), 7.62 (dd, J = 8.4 Hz, 18.0 Hz, 4 H), 7.03 (d, J = 16.3 Hz, 1
H); 13C NMR (75 MHz, DMSO-d6) δ 156.7, 149.4, 147.7, 140.4, 133.5, 132.2, 130.2, 126.6,
124.2, 115.1. Anal. Calcd for C12H8BrN3O4: C, 42.63; H, 2.38; N, 12.43; Br, 23.63. Found:
C, 42.41; H, 2.37; N, 12.27; Br, 23.55.
(E)-6-(4-Chlorostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (31)—A yellow
amorphous solid 31 (0.58 g, 67%): mp 326-328 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.68
(d, J = 16.2 Hz, 1 H), 7.60 (d, J = 8.4 Hz, 2 H), 7.51 (d, J = 8.4 Hz, 2 H), 7.03 (d, J = 16.3 Hz,
1 H); 13C NMR (75 MHz, DMSO-d6) δ 156.7, 149.6, 148.1, 140.0, 135.2, 133.3, 130.0, 129.2,
115.4. Anal. Calcd for C12H8ClN3O4: C, 49.08; H, 2.75; Cl, 12.07; N, 14.35. Found: C, 48.89;
H, 2.79; Cl, 11.89; N, 13.92.
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brickred amorphous solid 32 (625 mg, 67%): mp 298-300 °C. 1H NMR (300 MHz, DMSO-
d6) δ 11.83 (brs, 2 H), 8.38 (d, J = 2.8 Hz, 1 H), 8.14 (dd, J = 2.8, 9.0 Hz, 1 H), 7.83 (d, J =
16.4 Hz, 1 H), 7.34 (d, J = 16.4 Hz, 1 H), 7.07 (d, J = 9.0 Hz, 1 H); 13C NMR (75 MHz, DMSO-
d6) δ 162.8, 156.8, 149.3, 147.8, 138.9, 136.2, 127.1, 126.8, 126.0, 121.7, 156.9, 156.8;
negative ion EIMS m/z (rel intensity) 639 [2M − H+)−, 80], 319 [(M − H+)−, 100]. Anal. Calcd
for C12H8N4O7·0.75H2O: C, 43.19; H, 2.87; N, 16.79. Found: C, 43.38; H, 2.81; N, 16.68.
(E)-6-(2-Hydroxy-3-nitrostyryl)-3-nitropyrimidine-2,4(1H,3H)-dione (33)—A
yellowish-brown amorphous solid 33 (705 mg, 75%): mp 305-307 °C. 1H NMR (300 MHz,
DMSO-d6) δ 8.04 (dd, J = 2.8 Hz, 1 H), 7.97 (d, J = 7.8 Hz, 1 H), 7.90 (d, J = 16.4 Hz, 1 H),
7.24 (d, J = 16.4 Hz, 1 H), 7.09 (t, J = 8.0 Hz, 1 H); EIMS m/z (rel intensity) 321 (MH+, 32),
359 (MK+, 50), 659 (100); negative ion EIMS m/z (rel intensity) 319 [(M − H+)−, 100], 256
(11). Anal. Calcd for C12H8N4O7: C, 45.01; H, 2.52; N, 17.50. Found: C, 45.34; H, 2.55; N,
17.56.
(E)-6-(2-Methoxy-5-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (34)—A
yellow amorphous solid 34 (630 mg, 65%): mp 278-280 °C. 1H NMR (300 MHz, DMSO-d6)
δ 11.88 (s, 1 H), 11.73 (s, 1 H), 8.46 (d, J = 2.6 Hz, 1 H), 8.29 (dd, J = 2.6, 9.2 Hz, 1 H), 7.84
(d, J = 16.4 Hz, 1 H), 7.33 (d, J = 9.2 Hz, 1 H), 7.27 (d, J = 16.4 Hz, 1 H); 13C NMR (75 MHz,
DMSO-d6) δ 162.9, 156.7, 149.2, 147.8, 141.0, 134.9, 127.3, 126.8, 124.6, 123.5, 117.9, 112.9,
57.0; negative ion EIMS m/z 667 [(2M − H+)−, 100], 333 [(M − H+)−, 23]. Anal. Calcd for
C13H10N4O7·0.5H2O: C, 45.49; H, 3.23; N, 16.32. Found: C, 45.31; H, 3.04; N, 16.20.
(E)-6-(3-Hydroxy-4-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (35)—A pale
yellow amorphous solid 35 (323 mg, 69%): mp 310-312 °C. 1H NMR (300 MHz, DMSO-d6)
δ 11.73 (brs, 1 H), 11.19 (brs, 1 H), 7.94 (d, J = 8.6 Hz, 1 H), 7.66 (d, J = 16.3 Hz, 1 H), 7.30
(s, 1 H), 7.26 (d, J = 8.6 Hz, 1 H), 7.07 (d, J = 16.4 Hz, 1 H); 13C NMR (75 MHz, DMSO-
d6) δ 156.6, 152.3, 149.2, 147.2, 140.5, 139.1, 137.3, 127.0, 126.1, 118.6, 118.5, 118.1;
negative ion EIMS m/z 639 [(2M − H+)−, 100], 319 [(M − H+)−, 78]. Anal. Calcd for
C12H8N4O7: C, 45.01; H, 2.52; N, 17.50. Found: C, 44.98; H, 2.54; N, 17.45.
(E)-6-(4-Hydroxy-3-nitrostyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (36)—A
yellow amorphous solid 36 (315 mg, 67%): mp 320-322 °C. 1H NMR (300 MHz, DMSO-d6)
δ 11.83 (s, 1 H), 11.55 (brs, 1 H), 8.12 (d, J = 1.9 Hz, 1 H), 7.78 (dd, J = 1.9, 8.7 Hz, 1 H),
7.67 (d, J = 16.3 Hz, 1 H), 7.15 (d, J = 8.7 Hz, 1 H), 6.92 (d, J = 16.3 Hz, 1 H); 13C NMR (75
MHz, DMSO-d6) δ 156.7, 153.8, 149.4, 147.5, 139.8, 137.4, 134.3, 126.4, 125.7, 125.4, 119.9;
Pos EIMS m/z (rel intensity) 321 (M+, 100); negative ion EIMS m/z 639 [(2M − H+)−, 100],
319 [(M − H+)−, 30]. Anal. Calcd for C12H8N4O7: C, 45.01; H, 2.52; N, 17.50. Found: C,
44.70; H, 2.58; N, 17.44.
(E)-3-Hydroxy-4-(2-(5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-yl)vinyl)
benzoic Acid (37)—A yellow red amorphous solid 37 (0.28 g, 60%): mp 347-349 °C
(dec). 1H NMR (300 MHz, DMSO-d6) δ 11.91 (s, 1 H), 11.78 (s, 1 H), 10.82 (s, 1 H), 7.86 (d,
J = 16.3 Hz, 1 H), 7.57 (d, J = 8.1 Hz, 1 H), 7.49 (s, 1 H), 7.41 (d, J = 8.1 Hz, 1 H), 7.27 (d,
J = 16.3 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 167.2, 157.2, 157.1, 149.9, 148.0, 137.8,
133.5, 130.1, 126.8, 125.0, 120.4, 116.9, 116.1; negative ion EIMS m/z 637 [(2M − H+)−, 100],
318 [(M − H+)−, 27]. Anal. Calcd for C13H9N3O7·0.5H2O: C, 47.57; H, 3.07; N, 12.80. Found:
C, 47.35; H, 2.85; N, 12.56.
(E)-6-(2-Fluoro-3-methoxystyryl)-5-nitropyrimidine-2,4(1H,3H)-dione (38)—A
yellow amorphous solid 38 (115 mg, 65%): mp 318-320 °C. 1H NMR (300 MHz, DMSO-d6)
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δ 11.88 (s, 1 H), 11.85 (s, 1 H), 7.82 (d, J = 16.5 Hz, 1 H), 7.31 (t, J = 6.9 Hz, 1 H), 7.26 (m,
1 H), 7.21 (m, 1 H), 7.04 (d, J = 16.5 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 156.4, 151.2,
149.9, 147.8, 134.0, 127.0, 125.1, 122.9, 119.2, 116.4, 115.6, 56.5; negative ion EIMS m/z 613
[(2M − H+)−, 16], 306 [(M − H+)−, 100]. Anal. Calcd for C13H10FN3O5: C, 50.82; H, 3.28; N,
13.68; F, 6.18. Found: C, 50.46; H, 3.15; N, 13.44; F, 5.94.
(E)-5-Nitro-6-[2-(1H-pyrrol-2-yl)vinyl]pyrimidine-2,4(1H,3H)-dione (40)—A black
amorphous solid 40 (0.49 g, 68%): mp 302-304 °C (dec). 1H NMR (300 MHz, DMSO-d6) δ
7.71 (d, J = 16.0 Hz, 1 H), 7.13 (m, 2 H), 6.58 (d, J = 16.0 Hz, 1 H), 6.53 (m, 1 H), 6.21 (m, 1
H); 13C NMR (75 MHz, DMSO-d6) δ 156.8, 149.5, 147.9, 133.3, 132.4, 128.8, 117.52, 110.8,
105.2; negative ion EIMS m/z 495 [(2M − H+)−, 77], 247 [(M − H+)−, 100]. Anal. Calcd for
C10H8N4O4: C, 48.39; H, 3.25; N, 22.57. Found: C, 48.17; H, 3.51; N, 22.85.
(E)-6-(2-(Naphthalene-2-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione (43)—A
yellow amorphous solid 43 (0.66 g, 73%): mp 320-322 °C. 1H NMR (300 MHz, DMSO-d6) δ
11.73 (brs, 2 H), 8.11 (s, 1 H), 7.99 (m, 1 H), 7.93 (m, 1 H), 7.91 (d, J = 16.2 Hz, 1 H), 7.79
(d, J = 8.5 Hz, 1 H), 7.55 (m, 2 H), 7.13 (d, J = 16.2 Hz, 1 H); 13C NMR (75 MHz, DMSO-
d6) δ 157.0, 150.2, 149.1, 141.2, 133.8, 132.9, 132.0, 129.8, 128.8, 128.6, 127.7, 127.5, 126.9,
126.3, 123.8, 115.4; negative ion EIMS m/z 639 [(2MNa − 2H+)−, 100], 617 [(2M − H+)−, 22],
308 [(M − H+)−, 30]. Anal. Calcd for C16H11N3O4·0.75H2O: C, 59.54; H, 3.90; N, 13.02.
Found: C, 59.18; H, 3.46; N, 12.83.
(E)-6-(2-(3H-Indol-3-yl)vinyl)-5-nitropyrimidine-2,4(1H,3H)-dione (44)—A red
amorphous solid 44 (0.62g, 71%): mp 340-342 °C. 1H NMR (300 MHz, DMSO-d6) δ 12.10
(s, 1 H), 11.68 (s, 1 H), 11.53 (s, 1 H), 8.15 (d, J = 16.5 Hz, 1 H), 7.98 (d, J = 2.1 Hz, 1 H),
7.79 (d, J = 7.9 Hz, 1 H), 7.49 (d, J = 7.9 Hz, 1 H), 7.22 (m, 2 H), 6.85 (d, J = 16.5 Hz, 1
H); 13C NMR (75 MHz, DMSO-d6) δ 157.0, 149.6, 148.7, 137.8, 137.5, 132.5, 125.2, 124.6,
123.1, 121.6, 119.5, 112.9, 112.8, 106.3; negative ion EIMS m/z 319 [(MNa − 2H+)−, 66], 297
[(M − H+)−, 8]. Anal. Calcd for C14H10N4O4: C, 56.38; H, 3.38; N, 18.78. Found: C, 56.10;
H, 3.22; N, 18.76.
6-(Benzylamino)-5-nitropyrimidine-2,4(1H,3H)-dione (45)—6-Chloro-5-nitrouracil
(52) (0.15 g, 0.78 mmol), benzylamine (0.09 mL, 0.86 mmol) and Et3N (0.3 mL, 2.35 mmol)
in 1,4-dioxane (5 mL) were heated at reflux for 12 h. The mixture was cooled to room
temperature, filtered, and washed with methanol (5 mL) and ether (10 mL). The salt was
dissolved in dilute KOH solution, acidified with an excess of hydrochloric acid, and the solid
was filtered and washed with water (2 × 10 mL), methanol (2 × 10 mL) and then with ether (2
× 10 mL) and dried to yield a white amorphous solid 45 (145 mg, 73%): mp 284-286 °C. 1H
NMR (300 MHz, DMSO-d6) δ 7.30 (m, 5 H), 4.71 (s, 2 H); 13C NMR (75 MHz, DMSO-d6)
δ 157.1, 154.2, 147.6, 136.3, 128.7, 127.3, 126.4, 109.2, 46.5; EIMS m/z (rel intensity) 285
(MNa+, 100), 263 (MH+, 7); negative ion EIMS m/z (rel intensity) 261 [(M − H+)−, 100], 227
(7). Anal. Calcd for C11H10N4O4: C, 50.38; H, 3.84; N, 21.37. Found: C, 50.04; H, 3.69; N,
21.05.
6-(2-Hydroxybenzylamino)-5-nitropyrimidine-2,4(1H,3H)-dione (46)—6-Chloro-5-
nitrouracil (52) (0.27 g, 1.4 mmol), 2-hydroxybenzylamine (0.19 g, 1.56 mmol) and Et3N (0.6
mL, 4.23 mmol) in 1,4-dioxane (6 mL) were heated at reflux for 12 h. The mixture was cooled
to room temperature, filtered, and washed with methanol (5 mL) and ether (10 mL). The salt
was dissolved in dilute KOH solution, acidified with an excess of hydrochloric acid, and the
solid was filtered and washed with water (2 × 10 mL), methanol (2 × 10 mL) and then with
ether (2 × 10 mL) and dried to give a pale-yellow amorphous solid 46 (0.25 g, 64%): mp
138-140 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.84 (t, J = 5.4 Hz, 1 H), 9.72 (brs, 1 H), 7.25
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(dd, J = 1.3 Hz, 7.3 Hz, 1 H), 7.12 (m, 1 H), 6.75 (m, 2 H), 4.43 (d, J = 6.1 Hz, 2 H); 13C NMR
(75 MHz, DMSO-d6) δ 159.0, 158.7, 156.1, 130.7, 128.8, 125.4, 118.8, 116.7, 66.4; EIMS m/
z (rel intensity) 579 (2MNa+, 20), 380 (100), 301 (MNa+, 10); negative ion EIMS m/z (rel
intensity) 555 [(2M - H+)−, 100], 278 (M, 10), 277 [(M - H+)−, 85], 241. Anal. Calcd for
C11H10N4O5: C, 47.49; H, 3.62; N, 20.14. Found: C, 47.61; H, 3.69; N, 19.83.
6-(2-Hydroxy-2-phenethyl)-5-nitropyrimidine-2,4(1H,3H)-dione (47)—Lindlar
catalyst (5 mg) was added to a solution of compound 9 (100 mg, 0.36 mmol) in MeOH (5 mL).
A hydrogen balloon was attached and the mixture was stirred at room temperature for 12 h.
The reaction mixture was filtered through celite, which was then washed with MeOH (2 × 5
mL). The solution was concentrated and the residue was washed several times with CH2Cl2
(3 × 10 mL) and THF (3 × 10 mL). Finally, compound 47 was precipitated out by dissolving
in MeOH and adding excess diethyl ether to furnish the pure product (78 mg, 78%) as pale
yellow amorphous solid: mp 231-234 °C. 1H NMR (300 MHz, MeOH-d4) δ 7.06 (m, 2 H),
6.76 (m, 2 H), 2.88 (d, J = 6.8 Hz, 1 H), 2.85 (d, J = 5.6 Hz, 1 H), 2.70 (d, J = 5.6 Hz, 1 H),
2.67 (d, J = 6.8 Hz, 1 H); 13C NMR (75 MHz, MeOH-d4) δ 163.6, 156.4, 152.0, 135.8, 131.2,
128.9, 127.7, 120.7, 119.0, 116.0, 29.8, 29.1; negative ion ESI-MS m/z (rel intensity) 276 [(M
− H+)−, 100], 258 (15); HRMS m/z calcd for C12H11N3O5 (M − H+)− 276.0620, found
276.0619. Anal. Calcd for C12H11N3O5: C, 51.99; H, 4.00; N, 15.16. Found: C, 51.78; H, 4.28;
N, 15.04.
6-(4-Hydroxy-2-phenethyl)-5-nitropyrimidine-2,4(1H,3H)-dione (48)—Lindlar
catalyst (5 mg) was added to a solution of compound 16 (100 mg, 0.36 mmol) in MeOH (5
mL). A hydrogen balloon was attached and the mixture was stirred at room temperature for 12
h. The reaction mixture was filtered through celite, which was then washed with MeOH (2 ×
5 mL). The solution was concentrated and the residue was washed several times with
CH2Cl2 (3 × 10 mL) and THF (3 × 10 mL). Finally, compound 48 was precipitated out by
dissolving in MeOH and adding excess diethyl ether to furnish the pure product (70 mg, 70%)
as a yellowish amorphous solid: mp 235-237 °C. 1H NMR (300 MHz, MeOH-d4) δ 7.06 (d,
J = 8.4 Hz, 2 H), 6.69 (d, J = 8.4 Hz, 2 H), 2.80 (d, J = 6.5 Hz, 1 H), 2.77 (d, J = 5.6 Hz, 1 H),
2.68 (d, J = 5.6 Hz, 1 H), 2.65 (d, J = 6.5 Hz, 1 H); 13C NMR (75 MHz, MeOH-d4) δ 163.7,
157.0, 152.0, 135.4, 132.4, 130.5, 119.0, 116.3, 33.0, 31.9; negative ion ESI-MS m/z (rel
intensity) 276 [(M − H+)−, 100], 258 (33); negative íon HRMS m/z calcd for C12H11N3O5 (M
− H+)− 276.0620, found 276.0623. Anal. Calcd for C12H11N3O5: C, 51.99; H, 4.00; N, 15.16.
Found: C, 51.91; H, 4.21; N, 14.95.
5-Nitro-6-[(3-oxo-1,3-dihydroisobenzofuran-1-yl)methyl]pyrimidine-2,4-(1H,
3H)-dione (49)—a pale-yellow amorphous solid 49 (0.3 mg, 68%): mp 335-337 °C. 1H NMR
(300 MHz, DMSO-d6) δ 7.74 (m, 2 H), 7.56 (m, 2 H), 5.92 (dd, J = 3.0, 9.6 Hz, 1 H), 3.50 (dd,
J = 3.3, 13.8 Hz, 1 H), 2.86 (dd, J = 9.6, 13.8 Hz, 1 H); 13C NMR (75 MHz, DMSO-d6) δ
169.1, 156.4, 151.7, 149.1, 148.2, 134.8, 130.0, 128.0, 125.2, 125.0 122.8, 78.2, 35.1; negative
ion EIMS m/z (rel intensity) 302 [(M − H+)−, 100], 170 (61). Anal. Calcd for C13H9N3O6: C,
51.49; H, 2.99; N, 13.86. Found: C, 51.12; H, 3.08; N, 13.57.
5-Amino-(2-hydroxy-2-phenethyl)pyrimidine-2,4-(1H,3H)-dione (50)—
Concentrated HCl (0.5 ml) and 10% Pd/C (30 mg) were added to a solution of 5-nitro-6-
styryluracil (39) (300 mg, 1.16 mmol) in MeOH (10 mL). A hydrogen balloon was attached
and the mixture was stirred at room temperature for 24 h. The reaction mixture was filtered
through celite, which was then washed with 50% aq MeOH (5 mL) to provide compound 50
as a white solid (225 mg, 73%): mp 251-254 °C. 1H NMR (300 MHz, MeOH-d4/ D2O) δ 7.27
(m, 4 H), 7.23 (m, 1 H), 2.97 (m, 2 H), 2.85 (m, 2 H); 13C NMR (75 MHz, MeOH-d4) δ 160.1,
151.4, 150.1, 140.6, 129.8, 129.5, 127.9, 115.2, 34.4, 31.8; EIMS m/z (rel intensity) 231
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(M+, 51), 140 (M+ - C7H7, 80), 91 (M+ - C5H6N3O2, 100); CIMS m/z (rel intensity) 232
(MH+, 100). Anal. Calcd for C12H14ClN3O2: C, 53.84; H, 5.27; N, 15.70. Found: C, 53.99; H,
5.01; N, 15.90.
5-Amino-6-(2-hydroxyphenethyl)pyrimidine-2,4(1H,3H)-dione Hydrochloride
(51)—Pd/C (5 mg) was added to a solution of compound 9 (100 mg, 0.36 mmol) in MeOH
(20 mL). The mixture was shaken in Parr apparatus under H2 atmosphere for 24 h. The reaction
mixture was filtered through celite, which was then washed with MeOH (2 × 10 mL). The
solution was concentrated and the residue was washed several times with CH2Cl2 (3 × 10 mL)
and THF (3 × 10 mL). Finally, compound 51 was precipitated out by dissolving it in MeOH
and adding excess diethyl ether to furnish pure compound 51 (65 mg, 72%) as yellow
amorphous solid: mp 239-241 °C (dec). 1H NMR (300 MHz, MeOH-d4) δ 7.06 (m, 2 H), 6.75
(m, 2 H), 2.88 (d, J = 6.8 Hz, 1 H), 2.85 (d, J = 5.9 Hz, 1 H), 2.70 (d, J = 5.9 Hz, 1 H), 2.68
(d, J = 6.8 Hz, 1 H); EIMS m/z (rel intensity) 248 (MH+, 100), 194 (10), 230; HRMS m/z calcd
for C12H14N3O3 (MH+) 248.1035, found 248.1034. Anal. Calcd for C12H14ClN3O3: C, 50.80;
H, 4.97; N, 14.81. Found: C, 50.91; H, 4.81; N, 14.95.
Lumazine Synthase Assay—Assay mixtures contained 50 mM Tris hydrochloride, pH
7.0, 100 mM NaCl, 2% (v/v) DMSO, 5 mM dithiothreitol, 100 μM 2, lumazine synthase (Table
2), variable concentrations of 1 (3 – 150 μM) and inhibitor (0 – 150 μM) in a volume of 0.2
mL. Assay mixtures were prepared as follows. A solution (175 μL) containing 103 mM NaCl,
5.1 mM dithiothreitol, 114 μM 2, lumazine synthase in 51 mM Tris hydrochloride, pH 7.0,
was added to 4 μL of inhibitor in 100% (v/v) DMSO in a well of a 96-well microtiter plate.
The reaction was started by adding 21 μL of a solution containing 103 mM NaCl, 5.1 mM
dithiothreitol, and substrate 1 (30 – 1500 μM) in 51 mM Tris hydrochloride, pH 7.0. The
formation of 6,7-dimethyl-8-D-ribityllumazine (3) was measured online for a period of 40 min
at 27 °C with a computer-controlled plate reader at 408 nm (εLumazine = 10,200 M−1cm−1).
Riboflavin Synthase Assay—Assay mixtures contained 50 mM Tris hydrochloride, pH
7.0, 100 mM NaCl, 2% (v/v) DMSO, 5 mM dithiothreitol, enzyme (Table 2), variable
concentrations of 3 (3 – 20 μM) and inhibitor (0 – 150 μM) in a volume of 0.2 mL. Assay
mixtures were prepared as follows. A solution (175 μL) containing 103 mM NaCl, 5.1 mM
dithiothreitol, and riboflavin synthase in 51 mM Tris hydrochloride, pH 7.0, was added to 4
μL of inhibitor in 100% (v/v) DMSO in a well of a 96-well microtiter plate. The reaction was
started by adding 21 μL of a solution containing 103 mM NaCl, 5.1 mM dithiothreitol, and
substrate 3 (30 – 200 μM) in 51 mM Tris hydrochloride, pH 7.0. The formation of riboflavin
was measured online for a period of 40 min at 27 °C with a computer-controlled plate reader
at 470 nm (εRiboflavin = 9600 M−1cm−1).
Details of the Assay Procedures—For both lumazine synthase and riboflavin synthase
assays, four different inhibitor concentrations and seven different substrate concentrations were
used. Therefore, a series of measurements for one compound included 28 sample reactions
plus 4 reactions without substrate added (as control samples). The enzyme was added before
the reaction mixture was pipetted into different wells on a 96-well microtiterplate. The enzyme
concentration in all reaction mixtures was identical. After enzyme was added, the solution was
divided into four parts, and a different amount of inhibitor was added to each of them. The
accuracy of the measurements on the plate reader was checked regularly. An identical amount
of substrate was added to every well on the microtiter plate containing identical enzyme
solutions. The results of measurements were analyzed for all wells, and standard deviation
values were between 3% and 8%. The standard deviation values in Table 1 are important criteria
for determining the mode of inhibition, and do not reflect the accuracy of pipetting or
photometric measurements.
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Evaluation of Kinetic Data—The velocity-substrate data were fitted for all inhibitor
concentrations with a non-linear regression method using the program DynaFit. (Kuzmich
1996) Different inhibition models were considered for the calculation. Ki and Kis values ±
standard deviations were obtained from the fit under consideration of the most likely inhibition
model as described earlier.17
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This research was made possible by NIH grant GM51469, the Fonds der Chemischen Industrie, and the Hans Fischer
Gesellschaft. The experimental work was conducted in a facility constructed with support from Research Facilities
Improvement Program Grant Number C06-14499 from the National Center for Research Resources of the National
Institutes of Health.
References
1. Wang A. I Chuan Hsueh Pao 1992;19:362–368. [PubMed: 1466913]
2. Oltmanns O, Lingens F. Z Naturforschung 1967;22 b:751–754.
3. Logvinenko EM, Shavlovsky GM. Mikrobiologiya 1967;41:978–979.
4. Neuberger G, Bacher A. Biochem Biophys Res Commun 1985;127:175–181. [PubMed: 3838473]
5. Neuberger G, Bacher A. Biochem Biophys Res Commun 1986;139:1111–1116. [PubMed: 3094525]
6. Kis K, Volk R, Bacher A. Biochemistry 1995;34:2883–2892. [PubMed: 7893702]
7. Fischer M, Haase I, Feicht R, Schramek N, Kohler P, Schieberle P, Bacher A. Biol Chem
2005;386:417–428. [PubMed: 15927885]
8. Gerhardt S, Schott AK, Kairies N, Cushman M, Illarionov B, Eisenreich W, Bacher A, Huber R,
Steinbacher S, Fischer M. Structure 2002;10:1371–1381. [PubMed: 12377123]
9. Illarionov B, Eisenreich W, Bacher A. Proc Natl Acad Sci U S A 2001;98:7224–7229. [PubMed:
11404482]
10. Illarionov B, Eisenreich W, Schramek N, Bacher A, Fischer M. J Biol Chem 2005;280:28541–28546.
[PubMed: 15944152]
11. Illarionov B, Kemter K, Eberhardt S, Richter G, Cushman M, Bacher A. J Biol Chem
2001;276:11524–11530. [PubMed: 11278450]
12. Maley GF, Plaut GWE. J Biol Chem 1959;234:641–647. [PubMed: 13641276]
13. Plaut GWE. J Biol Chem 1963;238:2225–2243.
14. Plaut GWE, Harvey RA. Methods Enzymol 1971;18B:515–538.
15. Wacker H, Harvey RA, Winestock CH, Plaut GWE. J Biol Chem 1964;239:3493–3497. [PubMed:
14245407]
16. Volk R, Bacher A. J Am Chem Soc 1988;110:3651–3653.
17. Chen J, Illarionov B, Bacher A, Fischer M, Haase I, Georg G, Ye Qz, Ma Z, Cushman M. Anal
Biochem 2005;338:124–130. [PubMed: 15707942]
18. Kaiser J, Illarionov B, Rohdich F, Eisenreich W, Saller S, Van den Brulle J, Cushman M, Bacher A,
Fischer M. Anal Biochem 2007;365:52–61. [PubMed: 17400171]
19. Fischer M, Haase I, Feicht R, Richter G, Gerhardt S, Changeux JP, Huber R, Bacher A. Eur J Biochem
2002;269:519–526. [PubMed: 11856310]
20. Zhang YL, Illarionov B, Morgunova E, Jin GY, Bacher A, Fischer M, Ladenstein R, Cushman M. J
Org Chem 2008;73:2715–2724. [PubMed: 18331058]
21. Talukdar A, Illarionov B, Bacher A, Fischer M, Cushman M. J Org Chem 2007;72:7167–7175.
[PubMed: 17696548]
22. Zhang YL, Jin GY, Illarionov B, Bacher A, Fischer M, Cushman M. J Org Chem 2007;72:7176–
7184. [PubMed: 17705537]
Talukdar et al. Page 14













23. Chen J, Sambaiah T, Illarionov B, Fischer M, Bacher A, Cushman M. J Org Chem 2004;69:6996–
7003. [PubMed: 15471444]
24. Bacher A, Ludwig HC. Eur J Biochem 1982;127:539–545. [PubMed: 6816587]
25. Ritsert K, Huber R, Turk D, Ladenstein R, Schmidt-Bäse K, Bacher A. J Mol Biol 1995;253:151–
167. [PubMed: 7473709]
26. Morgunova K, Meining W, Illarionov B, Haase I, Jin G, Bacher A, Cushman M, Fischer M, Ladenstein
R. Biochemistry 2005;44:2746–2758. [PubMed: 15723519]
27. Morgunova E, Illarionov B, Sambaiah T, Haase I, Bacher A, Cushman M, Fischer M, Ladenstein R.
FEBS J 2006;273:4790–4804. [PubMed: 16984393]
28. Gerhardt S, Haase I, Steinbacher S, Kaiser JT, Cushman M, Bacher A, Huber R, Fischer M. J Mol
Biol 2002;318:1317–1329. [PubMed: 12083520]
29. Grahner B, Winiwarter S, Lanzner W, Muller CE. J Med Chem 1994;37:1526–1534. [PubMed:
8182711]
30. Nishigaki S, Kanamori Y, Senga K. Chem Pharm Bull 1980;28:1636–1641.
31. Senga K, Ichiba M, Nishigaki S. J Org Chem 1979;44:3830–3834.
32. Cresswell RM, Wood HSC. J Chem Soc 1960:4768–4775.
33. Ross WCJ. J Chem Soc 1948:1128–1135. [PubMed: 18884385]
Talukdar et al. Page 15














Hypothetical model of the complex of the lead compound 9 with M. tuberculosis lumazine
synthase. The distances shown are in Å. The diagram is programmed for wall-eyed (relaxed)
viewing.
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Hypothetical model showing hydrogen bonding between the phenolic hydroxyl group of
compound 46 with Ala59 and Glu61 of M. tuberculosis lumazine synthase. The distances
shown are in Å. The diagram is programmed for wall-eyed (relaxed) viewing.
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Table 2
Enzymes used in kinetic assays.
Enzyme Organism Specific activity μM mg−1 h−1 Concentration of enzyme in reaction mixture, μg mL−1
Lumazine synthases: S. pombe 6.8 1.0
M. tuberculosis 0.8 30
Riboflavin synthases: E. coli 21 0.8
M. tuberculosis 4.0 4.0
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